JP2015535282A5 - - Google Patents

Download PDF

Info

Publication number
JP2015535282A5
JP2015535282A5 JP2015540700A JP2015540700A JP2015535282A5 JP 2015535282 A5 JP2015535282 A5 JP 2015535282A5 JP 2015540700 A JP2015540700 A JP 2015540700A JP 2015540700 A JP2015540700 A JP 2015540700A JP 2015535282 A5 JP2015535282 A5 JP 2015535282A5
Authority
JP
Japan
Prior art keywords
combination according
sprm
composition
administration
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015540700A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015535282A (ja
JP6343619B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/066095 external-priority patent/WO2014070517A1/en
Publication of JP2015535282A publication Critical patent/JP2015535282A/ja
Publication of JP2015535282A5 publication Critical patent/JP2015535282A5/ja
Application granted granted Critical
Publication of JP6343619B2 publication Critical patent/JP6343619B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015540700A 2012-11-02 2013-10-22 プロゲステロン依存性病態を処置する方法およびその組成物 Expired - Fee Related JP6343619B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261722095P 2012-11-02 2012-11-02
US61/722,095 2012-11-02
PCT/US2013/066095 WO2014070517A1 (en) 2012-11-02 2013-10-22 Methods and compositions for treating progesterone-dependent conditions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018010276A Division JP2018062530A (ja) 2012-11-02 2018-01-25 プロゲステロン依存性病態を処置する方法およびその組成物

Publications (3)

Publication Number Publication Date
JP2015535282A JP2015535282A (ja) 2015-12-10
JP2015535282A5 true JP2015535282A5 (cg-RX-API-DMAC7.html) 2016-09-29
JP6343619B2 JP6343619B2 (ja) 2018-06-13

Family

ID=49510593

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015540700A Expired - Fee Related JP6343619B2 (ja) 2012-11-02 2013-10-22 プロゲステロン依存性病態を処置する方法およびその組成物
JP2018010276A Withdrawn JP2018062530A (ja) 2012-11-02 2018-01-25 プロゲステロン依存性病態を処置する方法およびその組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018010276A Withdrawn JP2018062530A (ja) 2012-11-02 2018-01-25 プロゲステロン依存性病態を処置する方法およびその組成物

Country Status (11)

Country Link
US (1) US9545411B2 (cg-RX-API-DMAC7.html)
EP (1) EP2914268B1 (cg-RX-API-DMAC7.html)
JP (2) JP6343619B2 (cg-RX-API-DMAC7.html)
CN (1) CN104755087A (cg-RX-API-DMAC7.html)
AU (1) AU2013338305B2 (cg-RX-API-DMAC7.html)
CA (1) CA2888377C (cg-RX-API-DMAC7.html)
ES (1) ES2688821T3 (cg-RX-API-DMAC7.html)
HK (1) HK1211852A1 (cg-RX-API-DMAC7.html)
IL (1) IL238403B (cg-RX-API-DMAC7.html)
MX (1) MX2015004821A (cg-RX-API-DMAC7.html)
WO (1) WO2014070517A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA46298A (fr) * 2015-05-18 2019-07-31 Bayer Pharma AG Modulateur sélectif du récepteur de la progestérone (sprm) pour son utilisation dans le traitement des saignements menstruels abondants
US20190008804A1 (en) * 2016-01-12 2019-01-10 Repros Therapeutics Inc. Trans-Clomiphene and Progesterone Receptor Antagonist Combination Therapy for Treating Hormone-Dependent Conditions
KR20210134927A (ko) 2019-02-28 2021-11-11 얀센 바이오테크 인코포레이티드 화농성 한선염의 치료를 위한 항-il-알파 항체
MX2022012967A (es) 2020-04-16 2023-01-18 Janssen Biotech Inc Tratamiento de la hidradenitis supurativa.

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2377418A1 (fr) 1977-01-13 1978-08-11 Roussel Uclaf Nouveaux derives steroides 4,9-dieniques 11b-substitues, leur procede de preparation et leur application comme medicaments
FR2521565B1 (fr) 1982-02-17 1985-07-05 Dior Sa Parfums Christian Melange pulverulent de constituants lipidiques et de constituants hydrophobes, procede pour le preparer, phases lamellaires lipidiques hydratees et procede de fabrication, compositions pharmaceutiques ou cosmetiques comportant des phases lamellaires lipidiques hydratees
FR2522328B1 (fr) 1982-03-01 1986-02-14 Roussel Uclaf Nouveaux produits derives de la structure 3-ceto 4,9 19-nor steroides, leur procede de preparation et leur application comme medicaments
FR2534487B1 (fr) 1982-10-15 1988-06-10 Dior Christian Parfums Procede d'homogeneisation de dispersions de phases lamellaires lipidiques hydratees, et suspensions obtenues par ce procede
WO1985002092A1 (en) 1983-11-14 1985-05-23 Bio-Mimetics Inc. Bioadhesive compositions and methods of treatment therewith
FR2598421B1 (fr) 1986-05-06 1988-08-19 Roussel Uclaf Nouveaux produits 19-nor ou 19-nor d-homo steroides substitues en position 11b par un radical phenyle portant un radical alkynyle, leur procede de preparation, leur application comme medicaments et les compositions les renfermant
US4954490A (en) 1988-06-23 1990-09-04 Research Triangle Institute 11 β-substituted progesterone analogs
US5077211A (en) 1988-07-06 1991-12-31 Applied Genetics, Inc. Purification and administration of dna repair enzymes
US5468741A (en) 1993-05-28 1995-11-21 The Regents Of The University Of California Use of low levels of mifepristone to treat leiomyomata
US5543150A (en) 1993-09-15 1996-08-06 Columbia Laboratories, Inc. Method of progesterone delivery and affect thereof
DE4426601A1 (de) 1994-07-27 1996-02-01 Schering Ag Verwendung eines Kombinationsproduktes enthaltend einen kompetitiven Progesteronantagonisten und ein Gestagen zur Herstellung eines Arzneimittels zur Behandlung der Endometriose oder des Leiomyomata uteri
EP0806952B1 (de) 1995-02-02 2003-04-02 Schering Aktiengesellschaft Verwendung von kompetitiven progesteronantagonisten für die herstellung von arzneimitteln zur behandlung von dysfunktionellen uterinen blutungen
EP0900234B1 (en) 1996-05-01 2000-07-05 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES 21-substituted progesterone derivatives as new antiprogestational agents
US6900193B1 (en) 1996-05-01 2005-05-31 The United States Of America As Represented By The Department Of Health And Human Services Structural modification of 19-norprogesterone I: 17-α-substituted-11-β-substituted-4-aryl and 21-substituted 19-norpregnadienedione as new antiprogestational agents
WO1998008471A1 (en) 1996-08-30 1998-03-05 The Population Council, Inc. Vaginal application mifepristone
US6682174B2 (en) 1998-03-25 2004-01-27 Silverbrook Research Pty Ltd Ink jet nozzle arrangement configuration
US6020328A (en) 1998-03-06 2000-02-01 Research Triangle Institute 20-keto-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties
EP1008443A1 (de) 1998-12-08 2000-06-14 Alusuisse Technology & Management AG Sterilisierbarer Folienverbund für Verpackungszwecke
US6740645B1 (en) 1999-09-03 2004-05-25 Research Triangle Institute 17β-acyl-17α-propynyl-11β-(cyclic amino) aryl steroids and their derivatives having antagonist hormonal properties
UA74168C2 (uk) 1999-10-05 2005-11-15 Коламбіа Леборетеріс (Бермуда) Лімітед Лікування ендометріозу або безпліддя, або покращення плідності та застосування бета-адренергічного агоніста для виробництва лікарського засобу
CA2403756C (en) 2000-03-17 2010-02-09 Hyun K. Kim Structural modification of 19-norprogesterone i: 17-.alpha.-substituted, 11-.beta.-substituted-4-aryl and 21-substituted 19-norpregnadienedione as new antiprogestational agents
IN191020B (cg-RX-API-DMAC7.html) 2000-03-28 2003-09-13 Dabur Res Foundation
AU1824302A (en) 2000-10-18 2002-04-29 Schering Ag Use of antiprogestins for prophylaxis and treatment of hormone-dependent diseases
WO2003005954A2 (en) 2001-07-09 2003-01-23 Zonagen, Inc. Methods and materials for the treatment of testosterone deficiency in men
JP4898431B2 (ja) 2003-04-29 2012-03-14 ザ ジェネラル ホスピタル コーポレイション 複数薬物の持続放出のための方法およびデバイス
EP1593376A1 (en) 2004-05-04 2005-11-09 Warner-Lambert Company LLC Improved pullulan capsules
NZ552720A (en) 2004-07-09 2010-02-26 Population Council Inc Sustained release compositions containing progesterone receptor modulators
GT200500185A (es) 2004-08-09 2006-04-10 Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos
AU2006227243B2 (en) 2005-03-22 2011-10-27 Allergan pharmaceuticals International Ltd. Dosing regimes for trans-clomiphene
JP2008536910A (ja) 2005-04-20 2008-09-11 ファイザー・リミテッド プロゲステロン受容体アンタゴニストとしてのピラゾール誘導体
DE102005030294A1 (de) 2005-06-24 2007-01-04 Schering Ag Nichtsteroidale Progesteronrezeptor-Modulatoren
EP1940413A1 (en) 2005-09-29 2008-07-09 Repros Therapeutics Inc. Formulations with improved bioavailability, comprising a steroid derivative and a polyglycolysed glyceride
CN1846703A (zh) 2006-02-13 2006-10-18 程定超 米非司酮阴道给药制剂及其组成和制备方法
US8173626B2 (en) * 2006-03-08 2012-05-08 Danco Laboratories Llc Methods, dosing regimens and medications using anti-progestational agents for the treatment of disorders
CA2673128C (en) 2006-10-24 2018-07-03 Repros Therapeutics Inc. Compositions and methods for suppressing endometrial proliferation
JP5379121B2 (ja) 2007-04-05 2013-12-25 ユニバーシティ・オブ・カンザス プルランを含む速溶性医薬組成物
US8569274B2 (en) 2007-04-20 2013-10-29 Preglem S.A. Progesterone antagonist and selective progesterone modulator in the treatment of excessive uterine bleeding
JP5555631B2 (ja) 2007-09-20 2014-07-23 ラピドット メディカル インポート アンド マーケティング リミテッド ミフェプリストンによる子宮平滑筋腫、平滑筋腫、筋腫、子宮類線維腫、子宮内膜症、または腺筋症を治療するための組成物および手段
TWI477276B (zh) * 2008-04-28 2015-03-21 Repros Therapeutics Inc 抗黃體素給藥方案
JP5992330B2 (ja) 2009-09-29 2016-09-14 メディメトリクス ペルソナリズド ドルグ デリヴェリー ベー ヴェ 物質を投与するための子宮内電子カプセル
UA113283C2 (xx) * 2010-12-23 2017-01-10 19-норстероїди і їх застосування для лікування прогестеронзалежних станів
WO2012121767A1 (en) * 2011-03-09 2012-09-13 Arstat, Inc. Treatment of uterine fibroids by intravaginal administration of a low dose of selective progesterone receptor modulator (sprm), anti-progestin, or anti-progestational agent
UA113291C2 (xx) 2011-08-04 2017-01-10 Метаболіти транскломіфену і їх застосування

Similar Documents

Publication Publication Date Title
JP2022022264A5 (cg-RX-API-DMAC7.html)
RU2011146058A (ru) Способ контрацепции, используемый по мере необходимости
CY1125254T1 (el) Μεθοδοι αγωγης μητρικων ινομυωματων και ενδομητριωσης
JP2013514984A5 (cg-RX-API-DMAC7.html)
JP2015535282A5 (cg-RX-API-DMAC7.html)
RU2018103064A (ru) Комбинация ингибитора hdac и анти-pd-l1-антитела для лечения злокачественной опухоли
FI3634419T3 (fi) Gonadotropiinia vapauttavan hormonin antagonistin käsittävä annostusohjelma kohdun myoomien hoitamiseksi ja kuukautisten aiheuttaman verenhukan vähentämiseksi
CN1652798A (zh) 连续抑制硫酸酯酶的孕激素的激素替代疗法
RU2016151303A (ru) Применение эрибулина в лечении рака
JP2015527360A5 (cg-RX-API-DMAC7.html)
CN1652797A (zh) 连续使用抑制硫酸酯酶的孕激素的避孕给药方案
AR049112A1 (es) Composiciones, metodos y kit, para el tratamiento de trastorno disforico premenstrual
JP2014529584A5 (cg-RX-API-DMAC7.html)
JP2017514851A5 (cg-RX-API-DMAC7.html)
JP2013522361A5 (cg-RX-API-DMAC7.html)
RU2019135630A (ru) Кобитолимод для применения при лечении воспалительного заболевания кишечника
EA201792524A1 (ru) Режим приема селективного модулятора рецептора прогестерона (sprm)
EA201491614A1 (ru) Способ лечения гинекологических заболеваний
CY1121190T1 (el) Δοσολογικη μορφη ανταγωνιστη υποδοχεα προγεστερονης
JP2013047269A5 (cg-RX-API-DMAC7.html)
US9795617B2 (en) Hormone delivery system and method
JP2017502989A5 (cg-RX-API-DMAC7.html)
Sharma et al. Centchroman regress mastalgia and fibroadenoma: An institutional study
TW200902028A (en) Combination of progesterone-receptor antagonist together with an aromatase inhibitor for use in BRCA mediated diseases
Pant et al. Luteal Phase Defect (LPD): A necessary tool in assisted reproductive techniques